Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFR^L858R/T790M

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) overexpression is linked to non-small cell lung cancer (NSCLC) pathogenesis.
• Acquired resistance mutations (EGFR^L858R/T790M) diminish the effectiveness of current EGFR inhibitors in NSCLC treatment.
• Novel therapeutic strategies targeting resistant EGFR mutations are crucial for improving NSCLC patient outcomes.

Purpose of the Study:

• To identify and characterize novel inhibitors targeting the EGFR^L858R/T790M resistant mutation in NSCLC.
• To evaluate the anti-cancer activity of the natural compound gossypol against NSCLC cells harboring the EGFR^L858R/T790M mutation.
• To elucidate the molecular mechanisms underlying gossypol's inhibitory effects on NSCLC progression.

Main Methods:

• Screening of a natural product library to identify EGFR^L858R/T790M inhibitors.
• In vitro assays including cell proliferation, apoptosis, and migration assays to assess gossypol's efficacy.
• Kinase activity assays, molecular docking, and Western blotting to investigate the inhibition mechanism and downstream signaling pathways.

Main Results:

• Gossypol demonstrated potent inhibition of NSCLC cell proliferation and migration.
• Gossypol induced caspase-dependent apoptosis in NSCLC cells, partly by upregulating the pro-apoptotic protein BAD.
• Molecular docking confirmed gossypol's binding to the EGFR^L858R/T790M kinase domain, with an EC₅₀ of 150.1 nM for kinase activity inhibition.
• Gossypol effectively inhibited EGFR phosphorylation and downstream signaling in a dose-dependent manner.

Conclusions:

• Gossypol exhibits significant anti-cancer effects against NSCLC by targeting the EGFR^L858R/T790M mutation.
• Gossypol's ability to inhibit proliferation, induce apoptosis, and block downstream signaling pathways makes it a promising candidate for NSCLC therapy.
• These findings provide a strong rationale for the further development of gossypol as a novel therapeutic agent for NSCLC patients with resistant EGFR mutations.